Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 73 matching trials from the live ClinicalTrials.gov search.
Conditions
Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Zoster Vaccine Recombinant, Adjuvanted
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Spring Valley, California • Wichita, Kansas • Uniontown, Pennsylvania
Conditions
Osteosarcoma, Neuroblastoma
Interventions
GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
2
States / cities
Houston, Texas
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
25
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more
Conditions
Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
Interventions
Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 15 Months
Enrollment
852 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
49
States / cities
Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Zostavax Vaccination in Rheumatoid Arthritis

NCT01506661
Conditions
Rheumatoid Arthritis, Varicella Zoster
Interventions
Zostavax (varicella zoster virus) vaccine
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
50 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more
Conditions
Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis, Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis, Enteropathic Arthritis, Crohn's Disease
Interventions
Herpes Zoster (HZ) Vaccine, Placebo
Biological · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 27 more
Conditions
Inflammatory Bowel Diseases, IBD
Interventions
Adjuvanted Recombinant Zoster Vaccine (RZV)
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Jacksonville, Florida • Baltimore, Maryland • New York, New York + 3 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly

NCT01331161
Conditions
Shingles
Interventions
ZOSTAVAX
Biological
Lead sponsor
Emory University
Other
Eligibility
25 Years to 79 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

NCT05703607
Conditions
Shingles, Herpes Zoster Infection, Human
Interventions
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
35
States / cities
Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Persistence of Protection by Shingrix

NCT04169009
Conditions
Herpes Zoster
Interventions
Zostavax, Shingrix
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 85 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Immunity; Defect Due to Antibody or Cell Mediated Immune Defect
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
60 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Kidney Transplant Recipients
Interventions
Varivax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
4
States / cities
Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Conditions
Herpes Zoster
Interventions
Encoding of data collected in Zoster 006 and Zoster 022 studies
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
26,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Mesa, Arizona • Phoenix, Arizona • Spring Valley, California + 26 more
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
7,539 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital

NCT01483378
Conditions
Herpes Zoster
Interventions
Choosing to receive the vaccine
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
New York, New York
Conditions
HIV Infections
Interventions
Varicella Virus Vaccine (Live)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 8 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
25
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 16 more
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
16,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Conditions
Immunosenescence, Shingles
Interventions
Varicella Zoster Virus Vaccine (Zostavax)
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Herpes Zoster
Interventions
Data collection
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
2,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Canton, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Systems Biology of Zoster Vaccine

NCT04047979
Conditions
Zoster, Zoster Varicella, Shingles, Chicken Pox
Interventions
Shingrix®
Biological
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
RSV Immunization
Interventions
RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 12 Months
Enrollment
2,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

NCT06581575
Conditions
Herpes Zoster (HZ), Infectious Diseases, Shingles
Interventions
JCXH-105, Shingrix
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
8
States / cities
Tucson, Arizona • Long Beach, California • Chicago, Illinois + 5 more